A Novel System for In Vivo Spectral Imaging of Tissues

组织体内光谱成像的新型系统

• 批准号: 6790460
• 负责人: Tomasz J Petelenz
• 金额: $ 40.75万
• 依托单位: STERLING RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-25 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6790460
• 关键词: bioimaging /biomedical imaging; biomedical equipment development; catheterization; clinical research; diagnosis design /evaluation; endoscopy; human subject; image guided surgery /therapy; imaging /visualization /scanning; neoplasm /cancer diagnosis; spectrometry

DESCRIPTION (provided by applicant): Sarcos Research Corporation proposes the development of a system for microinvasive examination of malignant tissues that will open new possibilities for performing cancer screening and diagnoses using a steerable and flexible microcatheter-mounted camera and sensors inserted via very small incisions/needles and convoluted passages, next to the tissues that are currently inaccessible without surgery. Sarcos will adapt its microcamera and microcatheter technology and prototype for use in minimally invasive in vivo detection and analysis of malignant tissues. This microcamera system will enable: image-guided diagnosis and therapy, micro-invasive, rapid in vivo accessibility of the tissues with an instrument or probe, and concurrent collection and interpretation both of the visual (image) and the spectral information using the light reflected from, or transmitted through the tissues. The microcatheteter-based endoscope will be flexible, maneuverable, biocompatible, sterile, disposable and economical. The proposed system will find applications to the detection of ovarian cancers, to examination of fallopian tubes, bladder, head and neck and CNS tissues and other difficult to access areas of the body. In Phase I effort, Sarcos will complete definitive feasibility demonstration of the proposed system for detection of malignant tissues using the proposed In Phase I effort, Sarcos will complete definitive feasibility demonstration of the proposed system for detection of malignant tissues using the proposed method. In order to accelerate the adaptation of the already developed system, Sarcos proposes a joint Phase I/II effort that will result in a validated system ready for a large scale clinical study and regulatory approval. PROPOSED COMMERCIAL APPLICATION: The proposed product will address the U.S. cancer diagnostic market that is presently estimated at $4 billion annually, including gynecology market of over $1 billion annually.

描述（由申请人提供）： Sarcos Research Corporation提议开发一种用于对恶性组织的微侵袭性检查系统的开发 目前无法访问没有手术。 Sarcos将适应其微型电视机和微型导管技术和原型，用于在体内检测和分析恶性组织中的微创。该微型拍摄系统将启用：图像引导的诊断和治疗，带有仪器或探针组织的微侵入性，快速的组织可及性，以及同时收集和解释，这两种 视觉（图像）和光谱信息使用反射或通过组织传播的光。 基于微量心电表的内窥镜将具有柔性，可操纵，生物相容性，无菌，一次性和经济性。拟议的系统将在检测卵巢癌，检查输卵管，膀胱，头颈和中枢神经系统组织以及其他难以进入人体区域的情况下发现应用。 在第一阶段的努力中，Sarcos将使用I阶段努力中提议的拟议系统来完成针对检测恶性组织的明确可行性，Sarcos将使用所提出的方法完成拟议系统检测恶性组织的确切可行性。 为了加速已经开发的系统的适应，Sarcos提出了联合I/II努力，该工作将导致经过验证的系统准备进行大规模的临床研究和监管批准。 拟议的商业应用程序：拟议的产品将解决美国癌症诊断市场，目前估计每年40亿美元，包括每年超过10亿美元的妇科市场。